secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001193125-24-011355
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian raises ~$150M in stock offering, reports $477M cash, outlines VRDN-003/001 trial timelines
--------------------------------------------------------------------------------

- Raised ~$150M gross from 7.14M shares at $21.00; underwriters have 30-day option for 1.07M additional shares.
- Preliminary cash and investments of $477.4M as of Dec 31, 2023; combined with offering expected to fund ops into H2 2026.
- VRDN-003: global pivotal trials in active and chronic TED planned to start mid-2024 pending regulatory alignment.
- VRDN-001: THRIVE Phase 3 topline in active TED expected mid-2024; THRIVE-2 chronic TED topline by year-end 2024.
- BLA package for VRDN-001 to include THRIVE, THRIVE-2 studies and safety database of ~300 treated patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524011355/0001193125-24-011355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524011355/d737189d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-011355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer